Durham, NC, United States · North America
OncologyRare diseaseCell & gene therapyVaccines
FDAEMAPMDANMPA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView OncologyCell & gene therapyRare diseaseVaccines
NMPAFDAEMAPMDA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView OncologyCell & gene therapyRare disease
NMPAFDA
SCALE 190 studies
Open to sponsorsSterile / advanced-therapy specialistView Durham, NC, United States · United States
Rare diseaseOncologyCell & gene therapy
FDAEMAPMDAMHRA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView OncologyVaccinesRare disease
NMPAFDAEMAPMDA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView Oncology
FDAEMAPMDANMPA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView OncologyVaccines
PMDAFDAEMANMPA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView E
Guildford, United Kingdom · Europe
OncologyRare disease
FDAEMAMHRA
SCALE 260 studies
Open to sponsorsAdvanced-therapy activeView Princeton, NJ, United States · United States
OncologyInfectious diseaseVaccines
FDAEMAMHRAHealth Canada
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView M
Cincinnati, OH, United States · United States
OncologyRare disease
FDAEMAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView OncologyCell & gene therapy
NMPAFDAEMAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView Morrisville, NC, United States · United States
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView OncologyRare disease
PMDAFDAEMANMPA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView PC
Zug, Switzerland · Europe
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView Oncology
EMAFDAMHRA
SCALE 240 studies
Open to sponsorsSelectiveView Oncology
PMDANMPAFDA
SCALE 260 studies
Open to sponsorsSelectiveView Oncology
FDANMPA
SCALE 220 studies
Open to sponsorsSelectiveView Company lists: Oncology & HematologyDermatologyNeuroscienceBiosimilar Development
SCALE 270 studies
Open to sponsorsGeneral clinicalView